Clinical Trial: Serotonin Norepinephrine Reuptake Inhibitors and the Risk of Serious Adverse Events

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07531173) titled 'Serotonin Norepinephrine Reuptake Inhibitors and the Risk of Serious Adverse Events' on April 09.

Brief Summary: This is a population-based retrospective, new-user design, active comparator cohort study assessing whether initiating a new outpatient prescription of high-dose serotonin norepinephrine reuptake inhibitors (SNRIs)-venlafaxine (>37.5-150 mg/day) or duloxetine (>30-120 mg/day), compared with low-dose SNRIs- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day), is associated with an increased 30-day risk of serious adverse events among older adults with low kidney function (estimated glomerular filtration rate [eGFR] 37.5-1...